ES2168006T3 - Factor neurotrofico ciliar modificado, metodo de fabricacion y metodos de utilizacion. - Google Patents

Factor neurotrofico ciliar modificado, metodo de fabricacion y metodos de utilizacion.

Info

Publication number
ES2168006T3
ES2168006T3 ES99911020T ES99911020T ES2168006T3 ES 2168006 T3 ES2168006 T3 ES 2168006T3 ES 99911020 T ES99911020 T ES 99911020T ES 99911020 T ES99911020 T ES 99911020T ES 2168006 T3 ES2168006 T3 ES 2168006T3
Authority
ES
Spain
Prior art keywords
modified
neurotrophic factor
manufacturing
use methods
ciliar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99911020T
Other languages
English (en)
Inventor
James P Fandl
Neil Stahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2168006T3 publication Critical patent/ES2168006T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)

Abstract

Un factor neurotrófio ciliar humano modificado, con la modificación Cys17!Ala, Gln63!Arg, y una deleción de los 15 restos de aminoácidos terminales.
ES99911020T 1998-02-27 1999-02-26 Factor neurotrofico ciliar modificado, metodo de fabricacion y metodos de utilizacion. Expired - Lifetime ES2168006T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/031,693 US6472178B1 (en) 1998-02-27 1998-02-27 Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof

Publications (1)

Publication Number Publication Date
ES2168006T3 true ES2168006T3 (es) 2002-05-16

Family

ID=21860892

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99911020T Expired - Lifetime ES2168006T3 (es) 1998-02-27 1999-02-26 Factor neurotrofico ciliar modificado, metodo de fabricacion y metodos de utilizacion.

Country Status (14)

Country Link
US (4) US6472178B1 (es)
EP (1) EP1056856B1 (es)
JP (1) JP4330796B2 (es)
AT (1) ATE212375T1 (es)
AU (1) AU749660B2 (es)
CA (1) CA2320402C (es)
DE (1) DE69900816T2 (es)
DK (1) DK1056856T3 (es)
ES (1) ES2168006T3 (es)
HK (1) HK1033336A1 (es)
IL (2) IL137858A0 (es)
NZ (1) NZ506267A (es)
PT (1) PT1056856E (es)
WO (1) WO1999043813A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
JP2003507393A (ja) * 1999-08-13 2003-02-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改変された毛様体神経栄養因子、それらを作製する方法およびそれらの使用方法
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
CN1500095B (zh) * 2001-02-01 2010-06-16 比奥根艾迪克Ma公司 神经胚活素的多聚体偶联物及其应用方法
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050064555A1 (en) * 2003-07-09 2005-03-24 Xencor, Inc. Ciliary neurotrophic factor variants
JP4765627B2 (ja) 2003-09-22 2011-09-07 Ｍｓｄ株式会社 新規ピペリジン誘導体
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
WO2006017156A2 (en) * 2004-07-09 2006-02-16 Regeneron Pharmaceuticals, Inc. Methods for identifying a candidate for treatment of obesity
CA2577060A1 (en) 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
KR101241551B1 (ko) 2004-08-19 2013-03-11 바이오겐 아이덱 엠에이 인코포레이티드 전환 성장 인자 베타 패밀리 단백질의 리폴딩
EP2127676A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related disorders
GB0425625D0 (en) * 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
RU2417985C2 (ru) 2005-05-30 2011-05-10 Баниу Фармасьютикал Ко., Лтд. Новые производные пиперидина
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
JPWO2007024004A1 (ja) 2005-08-24 2009-03-05 萬有製薬株式会社 フェニルピリドン誘導体
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE
CA2624030A1 (en) 2005-09-29 2007-04-12 Tianying Jian Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
CA2625416A1 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
EP1944301A4 (en) 2005-10-27 2012-01-04 Msd Kk NEW BENZOXATHIIN DERIVATIVES
US8158791B2 (en) 2005-11-10 2012-04-17 Msd K.K. Aza-substituted spiro derivatives
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
CA2664358A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diarylketimine derivative
US8592374B2 (en) * 2007-03-16 2013-11-26 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
US8796214B2 (en) * 2007-03-16 2014-08-05 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
US8796215B2 (en) * 2007-03-16 2014-08-05 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
EP2009103A1 (en) * 2007-03-16 2008-12-31 Ebewe Pharma Ges.m.b.H. Nfg. KG Neurotrophic peptides
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
NZ580947A (en) 2007-05-01 2012-05-25 Biogen Idec Inc Compositions and methods for increasing vascularization
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
DK2170930T3 (da) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 アルキルアミノピリジン誘導体
AU2009229860A1 (en) 2008-03-28 2009-10-01 Msd K.K. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
AU2009277736A1 (en) 2008-07-30 2010-02-04 Banyu Pharmaceutical Co., Ltd. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8796258B2 (en) 2011-02-25 2014-08-05 Merck Sharp & Dohme Corp. Cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
DK3186242T3 (da) 2014-08-29 2021-12-20 Tes Pharma S R L Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
EP3526199B1 (en) 2016-10-14 2022-04-13 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
EP3823674A4 (en) 2018-07-18 2022-12-28 Manzanita Pharmaceuticals, Inc. CONJUGATES FOR DELIVERING AN ANTI-CANCER AGENT TO NERVE CELLS, METHODS OF USE AND METHODS OF PRODUCTION THEREOF
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903130A1 (en) 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor
KR910016921A (ko) 1990-03-14 1991-11-05 파디아 에스. 피. 에이 인간의 모양체 신경원영양 인자, 그를 코딩하는 dna 서열 및 재조합 기술에 의한 그의 제조방법
IL98304A (en) 1990-06-01 2008-08-07 Regeneron Pharma The ciliary neurotrophic factor receptor
AU2925392A (en) * 1991-11-11 1993-06-15 Fidia S.P.A. Synthesis and purification of truncated and mutein forms of human ciliary neuronotrophic factor
WO1994008026A1 (en) * 1992-09-25 1994-04-14 Rhone-Poulenc Rorer S.A. Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
US5349056A (en) * 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
AU7204996A (en) * 1995-10-02 1997-04-28 Cytotherapeutics, Inc. Method for treating amyotrophic lateral sclerosis
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
KR20000070357A (ko) 1997-01-23 2000-11-25 다께우찌 마사야쓰 당뇨병 치료제

Also Published As

Publication number Publication date
NZ506267A (en) 2003-04-29
JP4330796B2 (ja) 2009-09-16
PT1056856E (pt) 2002-07-31
ATE212375T1 (de) 2002-02-15
DE69900816D1 (de) 2002-03-14
HK1033336A1 (en) 2001-08-24
US20030144199A1 (en) 2003-07-31
US7119066B2 (en) 2006-10-10
AU2976399A (en) 1999-09-15
CA2320402A1 (en) 1999-09-02
WO1999043813A1 (en) 1999-09-02
DK1056856T3 (da) 2002-05-06
IL137858A (en) 2008-04-13
JP2002504370A (ja) 2002-02-12
US6767894B1 (en) 2004-07-27
IL137858A0 (en) 2001-10-31
US6472178B1 (en) 2002-10-29
US20020123462A1 (en) 2002-09-05
CA2320402C (en) 2010-10-12
EP1056856A1 (en) 2000-12-06
DE69900816T2 (de) 2002-08-29
EP1056856B1 (en) 2002-01-23
AU749660B2 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
ES2168006T3 (es) Factor neurotrofico ciliar modificado, metodo de fabricacion y metodos de utilizacion.
ATE186305T1 (de) Perfluoroalkyll ketone, inhibitoren von elastase und prozess zur deren herstellung
DE69021153D1 (de) Medizinisches Ventil und Herstellungsverfahren, Katheter und Ventil sowie Kathetereinheit.
DE69527783D1 (de) System für die optimierung des kontinuierlichen, positiven atemwegdrucks zur behandlung des atemstillstandes im schlaf bei verlegten atemwegen
DE68900371D1 (de) Textile struktur zur herstellung von schichtstoffen und schichtformteile, die diese struktur enthalten.
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
DE69901177D1 (de) Platinkomplex, dessen herstellung und dessen therapeutische verwendung
IT1305313B1 (it) 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
IL139616A0 (en) Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating, diseases caused by deficiencies thereof
TR200200278T2 (tr) Kalsilitik bileşimler
NO984572L (no) Anvendelse av 2,5-dihydroksybenzensulfonderivater for fremstilling av legemidler ment for normalisering av den endoteliale funksjon, for behandling av seksuell dysfunksjon og vaskulµre komplikasjoner i diabetes, sÕvel som vaskulµre lidelser av e
AU8423401A (en) The treatment of inflammatory disorders
HK1043367A1 (en) Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments.
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
NZ514691A (en) Method to type prion proteins
HUP0203057A2 (hu) Módosított ciliáris nerotróf faktor, ennek előállítási és használati módszere
WO2001089550A3 (en) Use of ciliary neurotrophic factor
DE69906680D1 (de) Citronnellyl- und/oder dihydrocitronellyllactate, ihre herstellung und ihre anwendung
DE3870912D1 (de) 4,4'-(perfluorisopropyliden)dicyclohexanol, dessen abkoemmling und verfahren zur herstellung davon.
DE69023331D1 (de) Behandeltes hämoglobin und dessen herstellung.
HK1027825A1 (en) Use of arylguanidinium xanthogenates as vulcanization accelerators and process for the production thereof.
WO2002004636A8 (en) NOVEL α-CATENIN EXPRESSED IN HEART AND TESTIS
NL1015302A1 (nl) Werkwijze voor de productie van 2,3-dimethylbuteen-1 en 2,3-dimethylbuteen-2.